华支睾吸虫病伴胆囊癌及十二指肠类癌一例

患者,男,70岁.因进行性加重的腹胀3月余,合并黄疽半月入院,患者3个月前无明显诱因出现腹胀,开始上腹胀,餐后明显,伴嗳气,无腹痛、反酸,无恶心、呕吐,未行诊治,症状逐渐加重,波及全腹,同时伴乏力、纳差、消瘦,自觉腹部日见膨大,无发热,腹泻无明显浮肿,不尿,曾于外院查B超提示腹水,胆囊癌伴肝转移,进一步查螺旋CT支持B超诊断,给予对症治疗,具体用药不详,无效,于入院前半个月,病人出现皮肤巩膜黄染,尿色加深如浓茶,但无陶土便,收住我院消化科.     

阴茎多根金属异物存留一例报告

1 病例介绍 患者,男,63岁,农民,已婚离异27年.因阴茎不规则肿大20年,排尿困难伴尿道流血2d于2006年4月17日入院. 入院时查体:体温38℃,心肺正常,膀胱区稍膨胀,压痛,耻骨联合上水肿,暗红,阴茎不规则肿大,呈马铃薯样改变,大小约12cm×10cm×8cm,暗红色,质地中等,包皮呈苍白色,与海绵体粘连成硬结,表面有多处不规则突起,多个部位有分泌物溢出,尿道口呈十字形改变,龟头苍白,阴囊略水肿,睾丸正常.     

Vogt-小柳-原田综合征误诊1例报告

1临床资料 患者,男,29岁.入院前10d双眼视力突然下降,伴轻微头痛,曾就诊于其他医院,经眼科常规检查及眼部B超检查,诊断为原发性视网膜脱离,用药不详,因治疗效果不佳,于2002年10月18日来本院就诊.入院时自诉头痛明显,全身状况不佳,视力:右眼指数/1 m,左眼指数/1 m,双眼轻度睫状充血,角膜后可见细小点状沉着物,房水闪辉阳性,瞳孔呈药物性散大,直径5.5 mm,晶体不混浊,玻璃体可见条状混浊,眼压正常.     

贝科能致药物热1例

患者,女,49岁.因中上腹胀,厌油6d,尿黄2d,于2006年11月29日入院.患者6d前无明显诱因出现中上腹胀,与进食无关,略感厌油,无腹痛、腹泻,无纳差,无恶心、呕吐,无反酸、嗳气,无畏寒、发热.2d前,患者出现尿色变黄,并发现皮肤、眼睛发黄,嗳气,无皮肤瘙痒及皮疹,无胸痛、腹痛、畏寒、发热,无鼻NB024和牙龈出血,无关节红肿及疼痛,大便色黄.     

Submission Guide

Journal of Integrative Medicine(JIM)is an international,peer-reviewed,Pub Med-indexed journal,publishing papers on all aspects of integrative medicine,such as acupuncture and traditional Chinese medicine,Ayurvedic medicine,herbal medicine,homeopathy,nutrition,chiropractic,mind-body medicine,Taichi,Qigong,meditation,and any other modalities     

"肠覃"初探

1历史沿革与释义之争 "肠覃"二字最早见于<内经·灵枢·水胀第五十七>:"肠覃何如?岐伯日:寒气客于肠外,与卫气相搏,气不得荣,因有所系,癖而内著,恶气乃起,息肉内生,其始生也,大如鸡卵,稍以益大,至其成如怀子之状,久者离岁,按之则坚,推之则移,月事以时下,此其候也.石瘕何如?岐伯日:石瘕生于胞中,寒气客于子门,子门闭塞,气不得通,恶血当泻不泻,衃以留止,日以益大,状如怀子,月事不以时下,皆生于女子,可导而下."     

解读《神农本草经》

原文:夫大病之主有中风,伤寒,寒热,温疟,中恶,霍乱,大腹水肿,肠游,下痢,大小便不通,贲豚,上气,咳逆,呕吐,黄疸,消渴,留饮,癖食,坚积,症瘕,惊邪,癫痫,鬼疰,喉痹,齿痛,耳聋,目盲,金疮,踒折,痈肿,恶疮,痔,漏,瘿瘤,男子五劳七伤,虚乏羸瘦,女子带下,崩中,血闭,阴蚀。虫蛇蛊毒所伤。此大略宗兆,其间变动枝叶,各宜依端绪以取之。     

格林巴利综合征伴一过性高血糖性酮症酸中毒一例

1病例患者,女,49岁。10日前出现中上腹不适,伴恶心呕吐,并开始出现尿量减少,全身浮肿,四肢无力,双手不能持物,双下肢不能站立,当时无咖啡样     

经方新用治验1例

患者,男,50岁,煤矿职工。因发热、气喘、咳嗽2天,在村卫生所治疗未果,而前来卫生院就诊。患者面色苍白,发热恶寒,无汗,头不痛而重,微微气急,咳嗽响亮,咳痰,量少色白,口渴喜热饮。     

黄芪注射液静脉点滴过敏反应1例

患者,女,44岁,头晕、头痛、乏力,因长期植物神经功能紊乱,体质虚弱,并伴有失眠、多梦等症状,而住院治疗.治疗采取舒肝理气,养心安神,补气升阳的方法.给予5%葡萄糖液体250ml中加入20ml黄芪注射液,静脉点滴,大约10min后,病人突然出现胸闷、气短、心悸、畏寒,体温达39.8℃,随后出现意识不清、皮肤荨麻疹、面部肿胀,心率达120次/min.立即停止用药,给予10 mg地塞米松滴壶滴入,20min后患者进入睡眠状态,继而大汗淋漓,醒后意识清楚,生命体征基本恢复正常.     

Relevance of muscle biopsy for diagnosing multifocal motor neuropathy

Multifocal motor neuropathy （MMN） is a rare,.focal,inflammatory,demyelinating disease of the peripheral nerves with pure motor involvementJ MMN is clinically characterized by slowly progressive,asymmetric,distal,upper limb predominant weakness,in the absence of sensory disturbances） Weakness is usually multifocal and connected to a distinct motor nerve,such as the musculocutaneous nerve resulting in biceps weakness,the posterior interosseus nerve resulting in finger drop,the median,ulnar,or radial nerve resulting in dexterity problems or grip weakness,or the peroneal nerve resulting in a foot drop.Onset of clinical manifestations is between 20 and 50 years of age.The prevalence of MMN is reported as 1-2 per 100 000.2 MMN is three times more frequent in men as compared to women.     

高维列联表资料的统计分析与SAS软件实现（六）

非条件logistic回归分析方法的主要算法是采用最大似然法对参数进行估计。最大似然法在大样本前提下进行参数估计是非常有效的,但当处理样本量小的数据,特别是按多个定性变量进行分层且每一层中样本量很小时,     

细针穿刺对淋巴瘤诊断技术的价值

1文献来源Hehn ST,Grogan TM,Miller TR.Utility offine needle aspiration as a diagnostic technique inlymphoma[J].J Clin Oncol,2004,22（15）：3046-3052.     

Saffron （Crocus sativus L.） and major depressive disorder： a meta-analysis of randomized clinical trials

Due to safety concerns and side effects of many antidepressant medications, herbal psychopharmacology research has increased, and herbal remedies are becoming increasingly popular as alternatives to prescribed medications for the treatment of major depressive disorder （MDD）. Of these, accumulating trials reveal positive effects of the spice saffron （Crocus sativus L.） for the treatment of depression. A comprehensive and statistical review of the clinical trials examining the effects of saffron for treatment of MDD is warranted. OBJECTIVE： The purpose of this study was to conduct a meta-analysis of published randomized controlled trials examining the effects of saffron supplementation on symptoms of depression among participants with MDD. SEARCH STRATEGY： We conducted electronic and non-electronic searches to identify all relevant randomized, double-blind controlled trials. Reference lists of all retrieved articles were searched for relevant studies. INCLUSION CRITERIA： The criteria for study selection included the following： （1） adults （aged 18 and older） with symptoms of depression, （2） randomized controlled trial, （3） effects of saffron supplementation on depressive symptoms examined, and （4） study had either a placebo control or antidepressant comparison group. DATA EXTRACTION AND ANALYSIS： Using random effects modeling procedures, we calculated weighted mean effect sizes separately for the saffron supplementation vs placebo control groups, and for the saffron supplementation vs antidepressant groups. The methodological quality of all studies was assessed using the Jadad score. The computer software Comprehensive Meta- analysis 2 was used to analyze the data. RESULTS： Based on our pre-specified criteria, five randomized controlled trials （n = 2 placebo controlled trials, n = 3 antidepressant controlled trials） were included in our review. A large effect size was found for saffron supplementation vs placebo control in treating depressive symptoms （M ES = 1.62, P 〈 0.001）, revealing that saffron supplementation significantly reduced depression symptoms compared to the placebo control. A null effect size was evidenced between saffron supplementation and the antidepressant groups （M ES = -0.15） indicating that both treatments were similarly effective in reducing depression symptoms. The mean Jadad score was 5 indicating high quality of trials. CONCLUSION： Findings from clinical trials conducted to date indicate that saffron supplementation can improve symptoms of depression in adults with MDD. Larger clinical trials, conducted by research teams outside of Iran, with long-term follow-ups are needed before firm conclusions can be made regarding saffron＇s efficacy and safety for treating depressive symptoms.     

Hypercalcemic crisis due to a mediastinal parathyroid cyst diagnosed by ultrasound-guided fine needle aspiration

Hypercalcemic crisis, generally accepted as serum calcium concentration greater than 3.5 mmol/L,constitues a life-threatening endocrinologic emergency,and is most frequently caused by either primary hyperparathyroidism （PHPT） or malignant diseases.Parathyroid cysts are uncommon lesions, most of that are located in the low part of the neck. By routine neck ultrasound scan investigation in a large series of 6621 patients, only 5 parathyroid cysts were detected, yielding a prevalence of 0.075% in setting of unselected patients.The parathyroid cysts in the mediastinum are much less frequently encountered, with only 106 cases reported in English literature.2,3 Moreover, less than half of these cases presented as functional with elevated serum calcium and parathyroid hormone, and only 10 cases were associated with hypercalcemic crisis.3 Herein, we present a rare case of mediastinal parathyroid cyst associated with recurrent hypercalcemic crisis, which diagnosed by ultrasound-guided fine needle aspiration （FNA）.     

Association between intervertebral disc degeneration and disturbances of blood supply to the vertebrae

Low back pain is a common public health problem in western industrialized societies and the world as well.Studies indicate that the prevalence rate ranges to 35%, with around 10% of patients from 12% becoming chronically disabled. It also places an enormous economic burden on society. Although the exact cause of low back pain has yet to be defined, intervertebral disc degeneration is considered a major source of it. Since patients with degenerative discs are often asymptomatic, the mechanisms of it are still unclear.     

痘苗病毒天坛株的减毒与其作为疫苗载体研究进展

1痘苗病毒天坛株的历史天花是人类历史上最可怕的传染病之一。天花由天花病毒（variola virus）引起,人是该病毒的惟一宿主。人感染天花病毒后的死亡率达到30%~40%[1]。世界上公认的对天花最早的准确记录来自中国,晋代药学家葛洪于公元430年左右,在《肘后备急方》中对天花有清楚的描述[1]。     

Chinese herbal medicine Xinfeng Capsule in treatment of rheumatoid arthritis： study protocol of a multicenter randomized controlled trial

BACKGROUND： Rheumatoid arthritis （RA）, as a common systemic inflammatory autoimmune disease, affects approximately 1 in 100 individuals. Effective treatment for RA is not yet available because current research does not have a clear understanding of the etiology and pathogenesis of RA. Xinfeng Capsule, a patent Chinese herbal medicine, has been used in the treatment of RA in recent years. Despite its reported clinical efficacy, there are no large-sample, multicenter, randomized trials that support the use of Xinfeng Capsule for RA. Therefore, we designed a randomized, double-blind, multicenter, placebo-controlled trial to assess the efficacy and safety of Xinfeng Capsule in the treatment of RA. METHODS AND DESIGN： This is a 12-week, randomized, placebo-controlled, double-blind, multicenter trial on the treatment of RA. The participants will be randomly assigned to the experimental group and the control group at a ratio of 1：1. Participants in the experimental group will receive Xinfeng Capsule and a pharmaceutical placebo （imitation leflunomide）. The control group will receive leflunomide and an herbal placebo （imitation Xinfeng Capsule）. The American College of Rheumatology （ACR） Criteria for RA will be used to measure the efficacy of the Xinfeng Capsule. The primary outcome measure will be the percentage of study participants who achieve an ACR 20% response rate （ACR20）, which will be measured every 4 weeks after randomization. Secondary outcomes will include the ACR50 and ACR70 responses, the side effects of the medications, the Disease Activity Score 28, RA biomarkers, quality of life, and X-rays of the hands and wrists. The first four of the secondary outcomes will be measured every 4 weeks and the others will be measured at baseline and after 12 weeks of treatment. DISCUSSION： The result of this trial will help to evaluate whether Xinfeng Capsule is effective and safe in the treatment of RA. TRIAL REGISTRATION： This trial has been registered in ClinicalTrials.gov. The identifier is N CT01774877.